PDCD1 and pneumonitis: A recent meta-analysis by Nishino and colleagues (2016a) evaluated 20 studies involving approximately 4,500 patients participating in PD-1 inhibitor clinical trials and found the overall incidence for pneumonitis ranged from 0% to 10.6%.